PCH
APGE icon

Polar Capital Holdings’s Apogee Therapeutics APGE Stock Holding History

Polar Capital Holdings’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-539,177
Closed -$45.4M – 246
2026
Q1 		$45.4M Buy
539,177
+35,638
+7% +$2.59M 0.16% 106
2025
Q4 		$38M Sell
503,539
-20,555
-4% -$1.29M 0.15% 115
2025
Q3 		$20.8M Buy
524,094
+29,094
+6% +$1.11M 0.1% 146
2025
Q2 		$21.5M Sell
495,000
-55,000
-10% -$2.09M 0.11% 138
2025
Q1 		$20.5M Buy
+550,000
New +$21.3M 0.13% 146
2024
Q3 		– Sell
-250,000
Closed -$9.84M – 294
2024
Q2 		$9.84M Buy
+250,000
New +$12.1M 0.06% 187

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Polar Capital Holdings's APGE Position: Q2 2026 in Review

Polar Capital Holdings sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 539,177 shares — an estimated $45.4M sold.

Polar Capital Holdings first reported a position in APGE in Q2 2024 and held it in 6 quarters. The position peaked at $45.4M in Q1 2026. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Polar Capital Holdings reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Polar Capital Holdings sold 539,177 Apogee Therapeutics shares in Q2 2026, an estimated $45.4M.
  • Polar Capital Holdings first reported a position in Apogee Therapeutics in Q2 2024 and held it in 6 quarters.
  • Polar Capital Holdings's Apogee Therapeutics position peaked at $45.4M in Q1 2026.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.